BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38926094)

  • 1. Does a sFlt-1/PlGF ratio result > 655 before 34 weeks' gestation necessitate preterm delivery within 2 days? A retrospective observational study.
    Siepen C; Brennecke S
    J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2371047. PubMed ID: 38926094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of preterm birth in growth-restricted and appropriate-for-gestational-age infants using maternal PlGF and the sFlt-1/PlGF ratio-A prospective study.
    Hong J; Crawford K; Cavanagh E; da Silva Costa F; Kumar S
    BJOG; 2024 Jul; 131(8):1089-1101. PubMed ID: 38196326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.
    Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
    Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
    Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.
    Müller A; Horvat V; Vulin M; Mandić S; Šerić V; Vidosavljević D
    Med Glas (Zenica); 2019 Feb; 16(1):53-59. PubMed ID: 30680983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes.
    Bednarek-Jędrzejek M; Kwiatkowski S; Ksel-Hryciów J; Tousty P; Nurek K; Kwiatkowska E; Cymbaluk-Płoska A; Torbé A
    J Perinat Med; 2019 Sep; 47(7):732-740. PubMed ID: 31339858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.
    Villalaín C; Herraiz I; Valle L; Mendoza M; Delgado JL; Vázquez-Fernández M; Martínez-Uriarte J; Melchor Í; Caamiña S; Fernández-Oliva A; Villar OP; Galindo A
    J Am Heart Assoc; 2020 Apr; 9(7):e015548. PubMed ID: 32248765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. sFlt-1/PlGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical artery flow.
    Quezada MS; Rodríguez-Calvo J; Villalaín C; Gómez-Arriaga PI; Galindo A; Herraiz I
    Ultrasound Obstet Gynecol; 2020 Oct; 56(4):549-556. PubMed ID: 31840879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal change of sFlt-1/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction.
    Herraiz I; Quezada MS; Rodriguez-Calvo J; Gómez-Montes E; Villalaín C; Galindo A
    Ultrasound Obstet Gynecol; 2018 Nov; 52(5):631-638. PubMed ID: 28876491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia.
    Zeisler H; Llurba E; Chantraine F; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Dinkel C; Schoedl M; Dilba P; Hund M; Verlohren S
    Obstet Gynecol; 2016 Aug; 128(2):261-269. PubMed ID: 27399996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?
    Zhang K; Zen M; Popovic NL; Lee VW; Alahakoon TI
    J Obstet Gynaecol Res; 2019 Sep; 45(9):1828-1836. PubMed ID: 31257726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An sFlt-1:PlGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia.
    Stolz M; Zeisler H; Heinzl F; Binder J; Farr A
    Pregnancy Hypertens; 2018 Jan; 11():54-60. PubMed ID: 29523274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of competing-risks model with angiogenic factors in midgestation screening for preterm growth-related neonatal morbidity.
    Papastefanou I; Menenez M; Szczepkowska A; Gungil B; Syngelaki A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 May; 63(5):613-618. PubMed ID: 38057964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placental growth factor and fetoplacental Doppler indices in combination predict preterm birth reliably in pregnancies complicated by fetal growth restriction.
    Hong J; Crawford K; Cavanagh E; da Silva Costa F; Kumar S
    Ultrasound Obstet Gynecol; 2024 May; 63(5):635-643. PubMed ID: 37820083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of preterm birth in women with fetal growth restriction - Is the weekly change in sFlt-1/PlGF ratio or PlGF levels useful?
    Hong J; Crawford K; Cavanagh E; Clifton V; Kumar S
    Acta Obstet Gynecol Scand; 2024 Jun; 103(6):1112-1119. PubMed ID: 38483020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
    Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
    PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: The PEACOCK study.
    Duhig KE; Seed PT; Placzek A; Sparkes J; Hendy E; Gill C; Brockbank A; Shennan AH; Thangaratinam S; Chappell LC
    Pregnancy Hypertens; 2021 Jun; 24():90-95. PubMed ID: 33770588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study.
    Herraiz I; Simón E; Gómez-Arriaga PI; Quezada MS; García-Burguillo A; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2018 Jul; 13():279-285. PubMed ID: 30177066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.